News

For the fourth quarter of 2008, total revenues were $4.34 million, compared to $1.78 million in the same quarter of 2007. For 2008, total revenues were $14.97 million,

SNS-01 is a nano-encapsulated combination therapy of Factor5A and an siRNA against Factor 5A. These studies, undertaken to determine the efficacy, maximum tolerated dose and the feasibility of

This agreement gives Rhei the first option to license the exclusive rights for Skinvisible’s dermatology products for the territory of China, Hong Kong and Taiwan. Specifically the agreement

For the fourth quarter of 2008, total revenue was $811.3 million, up 2.8%, on robust sales to clinical diagnostics customers, partially offset by a decline in Life Sciences

This approval includes 24 EU member countries that take part in the Medicines and Healthcare products Regulatory Agency (MHRA) ‘mutual recognition procedure’. A similar application for the expanded

“The election of Peter Bambic as the new President and CEO of Adaltis Inc. comes at a very exciting time in the history of the Company, as we

For the fourth quarter of fiscal 2008, revenues were $37.8 million, compared to $40.4 million in the same quarter of fiscal 2007. For the full fiscal year ended

Mr Emmens has been a Vertex director since 2004, and previously served as CEO of Astra Merck, and of Shire, where he continues as chairman. Dr Boger, who

Internationally, the company is in the process of restructuring its sales and marketing business units in four countries in order to eliminate direct selling infrastructure costs. The company